Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hanna Fröhlich"'
Autor:
Johannes Schnorbach, Hanna Fröhlich, Tobias Täger, Anna Corletto, Hugo A. Katus, Lutz Frankenstein
Publikováno v:
ESC Heart Failure, Vol 6, Iss 4, Pp 640-648 (2019)
Abstract Aims Co‐morbid atrial fibrillation (AF) increases both mortality and N‐terminal pro brain natriuretic peptide (NT‐proBNP) concentrations in patients with chronic heart failure (CHF). It is unclear whether AF worsens prognosis independe
Externí odkaz:
https://doaj.org/article/7ead7e26785a4e2988705952dd4ee8cc
Publikováno v:
Cardiology. 147:529-538
Background: Obesity increases the risk of cardiovascular disease and heart failure (HF). However, in patients with established HF, many studies observed greater survival with increasing adiposity. This counterintuitive observation has been termed the
Autor:
Evangelos Giannitsis, Matthias Mueller-Hennessen, Hugo A. Katus, Lutz Frankenstein, Hanna Fröhlich, Tobias Täger, Katharina Hogrefe, Moritz Biener, Norbert Frey
Publikováno v:
Clinical Research in Cardiology. 111:333-342
Objective To evaluate the prognostic implications of longitudinal long-term changes beyond the biological variation of high-sensitivity cardiac troponin T (hs-cTnT) in outpatients with stable or asymptomatic cardiovascular disease (CV) and to assess
Autor:
Hanna Fröhlich, Norbert Frey, Bent Estler, Mirjam Mäck, Philipp Schlegel, Jan Beckendorf, Lutz Frankenstein, Tobias Täger
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 22(6)
Sacubitril/valsartan (S/V) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Data about the immediate, short-, and intermediate-term hemodynamic effects of S/V are limited.In this prospective observational study
Publikováno v:
Nutrition, metabolism, and cardiovascular diseases : NMCD.
While obesity has been linked to better ouctomes (the obesity paradox), cachexia is associated with higher mortality in patients with heart failure with reduced ejection fraction (HFrEF). As opposed to overt cachexia, little is known about the progno
Autor:
Lutz Frankenstein, Dan Atar, Stefan Agewall, Tobias Täger, Norbert Frey, John G.F. Cleland, Andrew L. Clark, Hanna Fröhlich, Morten Grundtvig
Background Receptor selectivity of sodium-glucose cotransporter-2 inhibitors (SGLT2i) varies greatly between agents. The overall improvement of cardiovascular (CV) outcomes in heart failure (HF) patients varies between trials. We, therefore, evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a19de253c1d0529f6e165779b313c9bd
https://eprints.gla.ac.uk/247161/1/247161.pdf
https://eprints.gla.ac.uk/247161/1/247161.pdf
Autor:
Hanna Fröhlich, Lutz Frankenstein, Tobias Täger, Johannes Schnorbach, Anna Corletto, Hugo A. Katus
Publikováno v:
ESC Heart Failure, Vol 6, Iss 4, Pp 640-648 (2019)
ESC Heart Failure
ESC Heart Failure
Aims Co‐morbid atrial fibrillation (AF) increases both mortality and N‐terminal pro brain natriuretic peptide (NT‐proBNP) concentrations in patients with chronic heart failure (CHF). It is unclear whether AF worsens prognosis independently from
Publikováno v:
Heart Failure Reviews. 24:461-472
The majority of patients with chronic heart failure (HF) receive long-term treatment with loop diuretics. The comparative effectiveness of different loop diuretics is unknown. We searched PubMed, clinicaltrials.gov , the Cochrane Central Register of
Autor:
Constantin von zur Mühlen, Hanna Fröhlich, Hugo A. Katus, Peter Stachon, Tobias Wengenmayer, Klaus Kaier, Raffi Bekeredjian, Manfred Zehender, Christoph Bode, Lutz Frankenstein, Tobias Täger
Publikováno v:
Clinical Research in Cardiology
Background The introduction of percutaneous mitral valve (MV) repair had an effect on clinical practice in comparison with surgical MV repair. Complete nationwide data are useful in examining how the introduction of a new technique influences clinica
Autor:
Andrew L. Clark, Hanna Fröhlich, Lutz Frankenstein, John G.F. Cleland, Dan Atar, Stefan Agewall, Tobias Täger, Hugo A. Katus, Morten Grundtvig
Publikováno v:
Heart Failure Reviews
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2D). The comparative efficacy of individual SGLT2i remains unclear. We searched PubMed, www.clinicaltrials.gov and the Coch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a763edb690cee48347192543cee6300
http://hdl.handle.net/10852/79863
http://hdl.handle.net/10852/79863